IES71050B2 - Nicotine-containing homeopathic dilution and its use in restoring neuronal function - Google Patents
Nicotine-containing homeopathic dilution and its use in restoring neuronal functionInfo
- Publication number
- IES71050B2 IES71050B2 IES960512A IES71050B2 IE S71050 B2 IES71050 B2 IE S71050B2 IE S960512 A IES960512 A IE S960512A IE S71050 B2 IES71050 B2 IE S71050B2
- Authority
- IE
- Ireland
- Prior art keywords
- nicotine
- dilution
- homeopathic
- water
- neuronal function
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims description 66
- 229960002715 nicotine Drugs 0.000 title claims description 66
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims description 65
- 238000010790 dilution Methods 0.000 title claims description 61
- 239000012895 dilution Substances 0.000 title claims description 61
- 230000001632 homeopathic effect Effects 0.000 title claims description 48
- 230000003955 neuronal function Effects 0.000 title claims description 12
- 239000003814 drug Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 244000061176 Nicotiana tabacum Species 0.000 claims description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 7
- 230000002650 habitual effect Effects 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 235000019505 tobacco product Nutrition 0.000 claims description 5
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 31
- 230000036515 potency Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 16
- 241000208125 Nicotiana Species 0.000 description 15
- 238000013207 serial dilution Methods 0.000 description 15
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 229940098465 tincture Drugs 0.000 description 11
- 150000007524 organic acids Chemical group 0.000 description 9
- 239000000779 smoke Substances 0.000 description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000013213 extrapolation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 210000003192 autonomic ganglia Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000004209 confusion Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 206010013395 disorientation Diseases 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000018997 giddiness Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000003152 motion sickness Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000037175 Travel-Related Illness Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 carbonium ion Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011037 discontinuous sequential dilution Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 229940015769 nicotine chewing gum Drugs 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Nicotine-containing homeopathic dilution and its use in restoring neuronal function
This invention relates to a homeopathic dilution of extracts of the plant Nicotiana tabacum including nicotine and its use in a method of restoring neuronal function in a subject whose normal neuronal function has been impaired.
The plant Nicotiana tabacum has been grown and used as a source of the drug nicotine for several centuries. The dried leaves and stalks of the tobacco plant support a substantial global commercial activity based on the social and recreational use of tobacco in various forms including a fine powder intended for sniffing, a moist wad intended for chewing and chopped or rolled leaves in cigarettes, cigars and pipes from which the smoke of smouldering tobacco is inhaled. In each form the active ingredient, nicotine, is absorbed systemically through mucous membranes of the nose, mouth, throat and lungs. Nicotine itself is recognised as an extremely addictive substance creating both a physical and psychological dependency resulting in habitual consumption of tobacco products. The health risks associated with tobacco consumption are well publicised by the world medical authorities and include mouth, throat and lung cancer, gastric and duodenal ulceration, cardiac and respiratory debilitation and predisposition to infectious disease.
The health authorities of most countries have a keen awareness of the need to encourage the population to stop consumption of tobacco products, but, due to the addictive nature of the principal drug substances, tobacco consumption continues largely unabated despite the associated health risks. The pharmaceutical industry has recognised the need to provide some substance to ameliorate the withdrawal symptoms and to help in overcoming the addiction. To date, apart from filters and other devices intended to reduce the nicotine content of the tobacco during consumption the major products available to the addict are nicotine chewing gum and nicotine transdermal patches. Each of these latter products contains substantial quantities of pure nicotine (greater
5711 Η» ’ than 1 mg) and is designed to allow the user to absorb nicotine into the systemic circulation through the skin, or mucous membranes of the mouth or nose, as appropriate. Both nicotine gum and nicotine transdermal delivery systems alleviate the major withdrawal symptoms by supplying pharmacologically detectable levels of nicotine to the systemic system, albeit generally at reduced levels in comparison with the consumption of tobacco itself; the mode of action is the same as that of nicotine absorbed from tobacco.
Nicotine exhibits a broad spectrum of activity on the central nervous system. The drug directly affects nicotinic cholinergic receptor sites. In low doses nicotine stimulates the autonomic ganglia and the respiratory process, it promotes the release of vasopressin and adrenaline and affects the serotonergic system. In low doses, it is also known to activate dopaminergic pathways, and, by stimulating the cholinergic neurones acting via the cortex on the hippocampus, it may improve the memory function; these low (or very low) dose effects may present beneficial properties particularly in Parkinson’s and Alzheimer’s disease, and conditions where cerebral insufficiency is generally present in geriatric senility.
In high doses nicotine inhibits neural impulses at autonomic ganglia and the neuromuscular junction ultimately resulting in respiratory paralysis and death.
A characteristic feature of all homeopathic dilutions is that they contain little or none of the original active constituent and rely on the derived properties of the succussed solvent to effect their therapeutic action. The exact mode of action of any homeopathic remedy is still unresolved in the scientific community. That homeopathic remedies work is a matter of accepted fact among both conventional (orthodox) and alternative medical practitioners and is illustrated by the scientific publications and reported therapeutic successes, from establishments such as The Royal London Homeopathic Hospital and as reported in articles such as “Clinical Trials in Homeopathy: The British Medical Journal, Kleignen etal. 1991. 302:316. Contemporary scientific research on the mode of action and therapeutic principle of homeopathic remedies is growing in intensity and has resulted in a variety of postulation and hypotheses from such eminent scientists as Dr. Colin B. Lessell: The Infinitesimal Dose'. C.W. Daniels & Co.
1994.
The fact that homeopathic remedies, in general, contain little or none of the original solute is the single most important feature which differentiates them from ‘orthodox’ remedies. The Avogadro Number quantifies the fact that the molecular weight, in grams, of any substance will contain 6.022 x 1023 molecules of that substance. Thus, the gram molecular weight of any substance when dissolved in one litre of water will by definition give a solution containing one mole, i.e. 6.022 x 1023 molecules in one litre. If this solution is then subjected to serial dilutions such that 1 ml of the solution (i.e. 6.022 x IO20 molecules) is dissolved in 9 ml of water to give 10 ml and after thorough mixing 1 ml of this is dissolved in 9 ml of water and so on until the 1:10 dilutions have been repeated twenty times then the twentieth sequential dilution will, by mathematical extrapolation, contain, on average, just
6.022 molecules of the substance in 10 ml of water. If this twentieth dilution is subjected to a further 1:10 dilution then the resulting solution will contain less than 1 molecule of the substance (on average 0.6022 molecules by mathematical extrapolation).
When using 1:10 dilutions, the homeopathist will frequently go beyond the twenty third dilution thereby obtaining a 'solution' which by the ‘Avogadro’ definition cannot contain any molecules of the original solute. Homeopathic dilutions are produced from 'mother tinctures' prepared according to the dictates of a homeopathic pharmacopoeia. While these mother tinctures are seldom prepared in anyway designed to give a defined molar concentration, their actual content of active ingredient has been measured by conventional analytical technique, and using this as a starting point, the subsequent serial dilutions are shown theoretically to result in a solution frequently containing none of the original solute.
There are three commonly used scales for serial dilution in homeopathy, these being 'X' or 1:10 dilution, 'C' or 1:100 dilution and ‘LM’ or 1:50,000. There are other less commonly used scales and variations on the theme of each, some of which combine X' dilutions initially followed by 'C' dilutions. The most common solvents are water, or a water solution of ethanol. Insoluble material is triturated by grinding with lactose in a pestle and mortar, initial dilution being effected by mixing dry powder and triturating with lactose. After a specified number of triturations , the serial dilution of lactose is dissolved in water or water:ethanol and liquid dilutions carried out thereafter. Just as dry powder (lactose) can be used in trituration to extract the homeopathic potency from an insoluble source, so too can liquid homeopathic potencies be used to endow the same property onto (or into) a dry powder final dose.
After each dilution the solution is succussed i.e. is shaken in an 'up and down' fashion, the downward stroke of each shake ending abruptly by impacting on a firm (but not brittle) surface. The number of shakes and the vigour of each is critical in developing the potency of each dilution. Succussion is proclaimed by the homeopathist to endow the solvent with some intangible aspect of the solute such that the solvent adopts the properties of the solute, and amplifies and reflects these properties when subjected to multiple serial dilutions and succussions.
The homeopathist describes the process of serial dilution as ‘dynamisation’ or ‘potentisation’ of the remedy and the administered dose regimen as posology; the potency of each dose being measured by the number of serial dilutions and labelled with that number and the scale of dilution used. For example a 15 ‘C’ remedy has been potentised by serial dilution 1:100, fifteen times with succussion after each dilution. The preparation of homeopathic remedies varies between practitioners and even between different National Formularies. There is almost universal acceptance in modem homeopathic practice that the process of succussion is fundamental to potentisation. The number of strokes, the frequency and vigour of each, contributing to 'better' potentisation is often standardised by utilising a mechanical device to effect the potentisation.
There is also variation in the solvent; the solvent will always 5 contain water, and mostly a water:ethanol mix. The serial dilutions are frequently carried out using a 14% v/v ethanol: water, and the final potency in 95% v/v ethanol:water. The variation in concentration of ethanol may reflect commercial considerations more than actual physical or chemical pre-requisites. The use of ethanol is commonly interpreted as being for the purpose of preservation. More recent research indicates however, that ethanol contributes to the potency of the dilution and this is thought to reflect the polar -OH group op the ethanol molecule which mimics (or is better than) the -OH polar water molecule in transferring and amplifying the endowed property of the original solute. Very little, if any, use is made of solvents other than water:ethanol, a fact which reflects the lack of exploratory research in homeopathy.
A comprehensive review of the current hypotheses on the mode of action of homeopathic remedies can be found in Dr. C. Lessell’s book, The Infinitesimal Dose, published by Daniel & Co., London 1994. Basically there are three levels of complexity in which most theories are rooted:
a) The geometrical level, at which polymers of molecular water are proposed to take up some conformity of shape which mimics the original solute.
b) The dynamic level in which electromagnetic vibration is in some way transferred from the solute to the solvent.
c) The submolecular level, where the concept of a chemical imprint being left in the water by the solute is postulated.
In accepting the fact that homeopathic remedies do work based on empirical medical evidence it is necessary then to understand the principles upon which each remedy is based. Hahneman’s principle is that of Similia Similibus Curentur or the law of similars; substances which produce a defined physiological symptom in healthy individuals can be used to cure similar symptoms produced by disease, if administered in the form of (very dilute) homeopathic potencies.
There are over 200 standard homeopathic remedies described in various homeopathic pharmacopoeias. Each remedy has been 'proven' by administering it - in undiluted form - to healthy individuals and carefully observing the symptoms it produces, fever, nausea, dizziness, pain, etc. A drug picture is then established and this is used to match as closely as possible - the symptomatic picture of a disease state. The fundamental principle in homeopathic prescription is the similimum or most similar in terms of correspondence between the symptomatological picture of the disease and that produced in healthy individuals during 'proving' of the homeopathic remedy.
Homeopathic remedies are frequently based on a drug substance which bears little or no relationship to the disease state; and the same disease (as categorised by orthodox medicine) may manifest itself in different symptoms in different individuals necessitating different homeopathic remedies.
A variation of classical homeopathy was developed by Wilhelm Lux (1831-1833) which is based on the principle of 'sameness' (Aequalia Aequalibus Curentur) as distinct from similars and is termed 'isopathy'. The principle is based on the use of a homeopathic dilution of the agent causing the disease as a treatment for the disease itself.
In classical homeopathy the remedy is based (generally) on some toxic substance which when administered undiluted causes similar symptoms in healthy people to those symptoms seen in sick people, (this is described as 'proving'). The high serial dilution of the same toxic substance can be considered to have been 'negatively charged’ in comparison to its 'positively charged' undiluted origin such that when administered to sick people it acts to quench the 'positive' symptoms and thus cure the disease. (The terms 'negatively charged' and 'positively charged’ are used only as a means of illustrating the principle involved and have no relation to the electric charges of the substance used.)
In classical isopathy the dilution can again be considered to have 5 been 'negatively charged' such that it re-balances an unwanted 'positive charge' e.g. allergic reaction to pollen (positive charge) which is quenched by the 'negatively charged' homeopathic potentisation of pollen.
Homeopathic dilutions of Nicotiana species are known and are referenced in Homeopathic Pharmacopoeias including the Homeopathic Pharmacopoeia of the United States, 7th Edition, published by Boericke & Tafel, 1011 Arch Street, Philadelphia. In this, the History and Authority (i.e. proving of the remedy) is referenced and accredited to ‘Hartlaub & Trinks’ in 1831. The clinical uses of the remedy are given as angina pectoris with coronaritis and high tension. Quite a number of contemporary publications reference the use of nicotine (homeopathic dilution of) as a remedy for travel sickness. See for example The Complete Family Guide to Homeopathy, Dr. Christopher Hammond published by Element Books, Shaftsbury, Dorset SP7 8BP in 1995. In this, as in other recent references, the use of nicotine is indicated for seasickness and for symptoms such as nausea, vomiting, vertigo, palpitations, pallor and sweating such as those which might arise in pregnancy, Meniere's Disease and heart disease. The use of the remedy in overcoming the withdrawal symptoms associated with cessation of tobacco consumption is not known because it does not fall within the classical framework of homeopathy or isopathy, and the symptomatological picture is not generally thought of as a 'disease'.
To date, the use of nicotine in orthodox dosages in the treatment of addiction to tobacco and/or/as a palliative for relieving the withdrawal symptoms associated with cessation of habitual abuse of nicotine-containing products has not proved generally successful for all of those wishing to overcome addiction to tobacco products.
The invention overcomes this problem by providing use of a homeopathic dilution of a nicotine-containing extract of the plant
Nicotiana tabacum in the manufacture of a medicament for use in a method of restoring neuronal function in a subject whose neuronal function has been impaired.
Thus, the medicament can be used to induce normal neuronal function in a subject whose normal neuronal function has been impaired by exposure to and tolerance of nicotine.
The medicament for use in accordance with the invention can 10 also be used to correct a condition characterised by cerebral insufficiency. Such conditions include Alzheimer's disease, Parkinson's disease and geriatric senility.
In particular, the medicament for use in accordance with the invention can be used as a palliative to relieve the withdrawal symptoms experienced by habitual users of tobacco products when the consumption of such products is interrupted.
By nicotine-containing extract of the plant Nicotiana tabacum herein is meant purified or partially purified constituents thereof, including nicotine.
The homeopathic dilution of nicotine is prepared according to the established procedures of serial dilution and succussion first described by Dr. Samuel Hahneman in his seminal text Essay on New Curative Principle in 1796.
According to the invention the disease state” is the symptomatological picture presented on removal of a toxic substance to which the addict has become tolerant. For example: inhalation of smoke from a cigarette will have very unpleasant effects on a nonsmoker, inducing dizziness, disorientation, nausea, and cardiac palpitations. Over a period the individuals nervous system becomes tolerant to the toxin, learning to use it for its 'stimulating* effects on cholinergic receptor sites, the nervous system then becomes addicted to it, developing a need for the toxin in order to function adequately.
On removal of the toxic substance, nicotine, the tolerant nervous system tries to recover its original functionality and reflects this relearning as withdrawal symptoms not unlike those associated with nicotine itself, in the non-addict; dizziness, disorientation, nausea, lack of concentration, sleeplessness, irritability.
In this situation the 'positively charged' symptoms were those first produced by exposure to nicotine, which over the course of time have become hidden by the induction of tolerance to the toxin. The application of a 'negatively charged' homeopathic dilution of the same toxin acts as a rapid re-induction of normal neuronal and cerebral function and so relieves the withdrawal symptoms. In this case the therapeutic principal is neither classical homeopathy or isopathy as nicotine withdrawal the disease state is not generally recognised as a disease, and this remedy differs totally from the orthodox approach which is to present nicotine in pharmacologically detectable amounts from an alternative source (chewing gum/transdermal patch). This invention utilises the homeopathic potentisation technique to extract from, and endow the solvent with, the ‘negative charge’ properties of the tolerated toxin, which is then used to affect normal intolerance of the toxin and normal neuronal functionality. Should any trace level of the original solute remain in the dose it is several orders of magnitude below that which is usually considered to be pharmacologically detectable, (i.e. the orthodox dose as administered in gum or transdermal patches).
Preferably, a mother tincture used to prepare the medicament contains nicotine or a salt thereof.
In most preferred embodiment the dilution of mother tincture used to prepare the medicament contains nicotine base.
The mother tincture used to prepare the medicament for use in accordance with the invention may contain an amount of an alkali.
In order to stabilise the free base nicotine during the succussion process it may be desirable to introduce a suitable alkali such as ammoniun ion, thus minimising any interaction with, for example, a carbonium ion from dissolved CO2.
Preferably the homeopathic dilution is a 2'C*-15'C* dilution of mother tincture.
Homeopathic remedies increase in potency as they are diluted, in this invention the lowest potency applicable is a 2’C' dilution containing less than 1 nanogram of the original active ingredient, there is no known or theoretical maximum potency (dilution) but potencies greater than 15'C’ should be administered with extreme caution.
The medicament in accordance with the invention can be administered in various forms. Preferably, the formulation is administered in the form of oral drops, a solid oral dose, as an intranasal spray or as a suppository designed for administration per rectum.
The medicament can also be administered orally using sustained release formulations such as a chewing gum or as a muco-adhesive polymer. Other suitable formulations include sustained release formulation administered by way of a transdermal delivery system.
Preferably, the final dilution of the homeopathic dilution contains a nicotine-potentiating agent.
In one embodiment, the nicotine-potentiating agent is an organic acid or a polymer or co-polymer which contains an organic acid as a repeating monomeric unit.
Suitably the organic acid is selected from acetic acid, ascorbic acid, citric acid, lactic acid, glycolic acid or a mixture thereof.
Most especially the organic acid is acetic acid.
In accordance with the invention one can utilise acetic acid as a final diluent with water and/or ethanol: the initial low potency dilutions having been prepared in water only. In preliminary trials acetic acid was found to dramatically amplify the empirical effects of 15'C' potency of nicotine. Although not wishing to be bound by any theoretical explanation of the invention, this effect probably results from the presence of the terminal -OH moiety in the -COOH acetate group in acetic and other organic acids.
Nicotine is a weak base and readily forms salts with any organic acid. It is known that salts of nicotine are less toxic and do not penetrate the mucous membranes as easily as the free base. For this reason, only the final dose is diluted in ethanol.acetic acid.water, all preliminary serial dilutions (l’C* - 14'C) being in water only.
In preliminary trials a 50:50 ethanol: IN acetic acid solution was used to prepare a final '15C' potentisation of pure nicotine. In a single volunteer this potency gave substantially greater effects than a similar '15C' potency prepared at the same time using 50:50 ethanol: water.
As indicated above, the dissociation of acetic acid in water and ethanol may increase the relative polarity of the ethanol and this may or may not be a contributing factor in 'locking up' the endowed properties of the original solute. Further development of the solvent characteristics would be possible by introducing electron withdrawing or donating groups on the ethanol or acetic acid to improve the overall electronegativity of the solvent.
In a further embodiment, the nicotine-potentiating agent is an alkaloid.
Suitably, the potentiating agent is caffeine. The use of caffeine has been found to amplify the effects of the original solute.
The use of low background concentrations of caffeine as a weak base was evaluated. A 0.1 % w/v solution of caffeine in water was used as the diluent throughout all potencies to arrive at 15’C' homeopathic dilutions of nicotine in 0.1% w/v caffeine. Again this method was subjectively judged to have greatly enhanced the therapeutic effect of the nicotine.
The invention also provides a homeopathic dilution of a nicotinecontaining extract of the plant Nicotiana tabacum wherein the final dilution contains a nicotine-potentiating agent.
As indicated above, the nicotine-potentiating agent is suitably an organic acid or a polymer or co-polymer which contains an organic acid as a repeating monomeric unit.
The organic acid is suitably selected from acetic acid, ascorbic acid, citric acid, lactic acid, glycolic acid or a mixture thereof, especially acetic acid.
As indicated above, the nicotine-potentiating agent can also be an alkaloid, preferably a plant alkaloid such as caffeine
In order to define dose limits and so differentiate this invention from orthodox remedies it can be stated that the medicament according to the invention is diluted to the point where a single dose will contain less than 1 nanogram of the original active ingredient (nicotine) and that the therapeutic effect is subjectively detectable even when diluted beyond the point where there can be any certainty that any one dose contains even one molecule of the original solute based on the Avogadro Number. If the original ’mother tincture' or solution of extract from Nicotiana species is shown, by conventional analysis, to be 1.0 Molar solution (or any other concentration). And if the process of homeopathic dilution and potentisation results in a volume of (say) 1.0 litre which has been subjected to serial dilution such that the final volume of (say) 1.0 litre contains less than 200 molecules of the original solute (by mathematical reduction of the Avogadro Number), then there is no certainty that a 5 ml dose (1/200 of the final volume) will contain even one molecule of the original solute. In this invention the dose may be an aliquot of a solution where the theoretical number of molecules in the total volume is less than the total number of dose aliquots in that solution, and will always be an aliquot of a solution where the concentration of solute is such that a single dose is less than 1 nanogram of active principal and is produced by serial dilution and succussion.
For example:
The formula weight of pure nicotine is 162.2 grams (C10H14N2). The compound is a liquid with a density of 1.02 g per ml.
159 ml of pure nicotine (162.2 /1.02) diluted to 1.0 litre with water will provide a 1 molar solution i.e. 1 gram molecular weight in 1 litre and will by definition contain 6.022 x 1023 molecules of pure nicotine.
If this solution is subjected to serial dilution 1:100, ten times, by definition it will contain 6.022 x 103 or 6,022 molecules of nicotine.
1.0 ml will contain 6.022 molecules, 0.1 ml or one drop will contain 0.6022 molecules.
According to the invention the dose may be one drop (0.1 ml) of a 10 ‘C’ or greater dilution of a 1.0 molar solution of nicotine, suitably potentised by homeopathic succussion, or similar dilutions designed to produce a solution from a ’mother tincture* such that the dose administered is less than 1 molecule of the active ingredient.
The following rationale serves to further illustrate the limits of dilution and dose content of active ingredient.
Nicotine: Formula Weight = 162.2 grams
Density = 1.02 grams per ml
159 ml = 162.2 grams
159 ml made up to 1.0 litre with water = 1 molar solution 1 molar solution contains 6.022 x 1023 molecules of nicotine r ml of this 1 molar solution contains 6.022 x IO20 molecules (one thousandth of 1 molar) ,
1 ml also contains 162.2 g/1,000 or 0.162 grams
Therefore 1 ml in 99 ml of water = 1/100 or l'C' dilution, contains (per ml)
6.022 x 1018 molecules or 0.001622 grams i.e.
1.622 mg nicotine.
ml of the above l'C' dilution in 99 ml of water will give a 2’C' dilution containing (per ml)
6.022 x 1016 molecules or
0.01622 mg i.e. 16.22 nanograms nicotine ml of the above 2'C' dilution will contain
6.022 x 1014 molecules or 0.1622 nanograms nicotine
The invention will be further illustrated by the following Examples:
Example 1
A mother tincture of Nicotiana tabacum was prepared according to the U.S. Homeopathic Pharmacopoeia as follows:
Tabacum in coarse powder (dried tobacco leaves) 100 g. Purified water 200 ml. Strong alcohol 824 ml.
To make 1 litre of mother tincture with a drug strength of
1/10.
In the Pharmacopoeia potencies which may be used are given as '2 x' (2 x 1:10 dilutions) and higher with dispensing alcohol. The prescribed dose is given as the third to thirtieth potency.
Example 2
Smoke from 5 g. of smouldering leaves of Tabacum nicotiana was slowly sparged into 1.0 litre of 50:50 v/v solution of ethanol water. This 'mother tincture' was an acrid brown solution which was considered to contain 5 mg of nicotine in 1 litre. By definition this solution contained 1.856 x 1019 molecules of nicotine in total.
Nicotine Formula Weight = 162.2 g.
162.2 g = 6.022 x 1023 molecules mg = 162.2/0.005 g = 1/32440
6.022 x 1023/32440= 1.856 x 1019
A '20 x' serial solution was prepared from this, 1:10 with succussion after each dilution, using water, the final 20’X' dilution » being prepared in 50:50 ethanokwater.
*
The resulting solution contained 0.185 molecules of nicotine.
This '20 x' potency was tested for efficacy in relieving nicotine withdrawal symptoms, in a single volunteer nicotine addict (i.e. habitual user of tobacco). After a period of 12 hours abstinence from nicotine one drop of this ’20 x' potency was applied to the tongue and held in the mouth for 30 seconds before swallowing. After approximately one minute the volunteer reported a sense of tightness at the back of the neck, this was followed shortly by a sense of elation and ‘giddiness’ which lasted for about one hour. There was no desire to obtain nicotine from tobacco for a period of about six hours, thereafter.
Example 3
In order to obtain a standardised ‘mother tincture’ a 98% - 100% pure preparation of a naturally occurring isomer of (-) nicotine was obtained from The Sigma Company, Poole, Dorset, U.K. The compound has a formula weight of 162.2 grams and a density of 1.02g/ml.
159 ml of this made up to a volume of 1.0 litre representing a 1 molar solution.
1:100 centessimal or 'C' dilutions were carried out using water as a diluent. After each dilution the solution was subjected to 100 succussion strokes.
’12C' and ’15C* potencies were prepared i.e. 12 x 1:100 dilutions and 15 x 1:100 dilutions, both of which were used to test the efficacy of the remedy in alleviating the symptoms of nicotine withdrawal.
By mathematical extrapolation the '12C' potency of this solution contains 0.6022 molecules in the total volume of 1 litre; the '15C' dilution contains 0.0000006 molecules - (none). The dose was chosen arbitrarily using a medicine dropper designed to deliver 2.0 ml (in homeopathy the dose volume is not critical). Each dose was dropped onto the back of the tongue and held there without swallowing for 30 seconds.
Volunteer 1
Healthy teenage (17) female casual smoker.
The volunteer had refrained from smoking for 12 hours and expressed a mild desire to smoke. On application of the ‘12 C’ remedy the volunteer reported giddiness, elation and a feeling of well being; the desire to smoke was absent until a further 12 hours had elapsed.
Volunteer 2
Healthy teenage (15) male had never smoked and disliked the habit in others. On administration of the ‘12C’ remedy the volunteer reported a sense of bad taste in the remedy and experienced no tangible symptoms other than some irritability in his throat.
Volunteer 3
Healthy 43 year old female smoking cigarettes for over 25 years, showing no physical symptoms of disease other than a mild infrequent cough.
On application of the ‘15C’ remedy the volunteer reported a bad taste followed by a sense of lightness and relaxation; the desire to smoke was absent for over 6 hours.
Volunteer 4
Healthy 44 year old male, smoking cigarettes for over twenty years with a few periods of abstinence in that time. The remedy ‘15C’ was administered on wakening in the morning and the volunteer refrained from the normal habit of smoking during the early part of the day. The volunteer reported that the normal urge to smoke was absent and there was a feeling of lightness and well being. Further administrations of the same remedy at four hourly intervals during the day provided a sustained sense of well being and elation. The normal urge to smoke was not experienced in anything like the intensity normally felt by an addict opting for temporary suspension of the drug.
Example 4
Using the same procedure as in Example 3 except replacing the water at the 15 'C' dilution with 50:50 ethanol:IN acetic acid.
Volunteer 4 compared the effects of the T5C’ ethanokacetic acid potency with the 15’C' water potency on two successive days.
The day after the water remedy had been tested the exact same procedure was used this time utilising the ethanokacetic acid dilution. The empirical effects were much greater, more immediate and seemed to last longer. The effects were the same, lightness and elation and loss of a desire to smoke. The only observation which was different was a ‘sour taste’ which was accounted for by the acetic acid.
Example 5
Using the 1 molar solution of nicotine in water from Example 3 as 'The Mother Tincture' a 15'C' remedy was prepared using a 0.1% w/v aqueous solution of caffeine as the diluent. By subjective analysis Volunteer 4 considered the caffeine/nicotine potency to be superior in effect to either the 15'C' water or the 15'C' ethanol:IN acetic acid potencies. At present there is no known analytical technique which can be used to compare the potencies of these homeopathic remedies, therefore subjective analysis awaits confirmation in large scale clinical trials.
The in-vivo testing carried out to date is limited to a small number of volunteers because of Regulatory Authority controls on preapproval for clinical trials.
The small population study described above contained some reported anomalies such as the 'bad taste' from Volunteers 2 and 3, and the fact that the remedy had little or no reported effect on Volunteer 3. These are not unusual effects in homeopathic remedies; the bad taste is frequently remarked on and is one of the indications that some aspect of the solute has remained in the solvent even though the process of dilution is known to have exceeded the molecular concentration. The lack of any specific effect in the one volunteer who had never smoked is also characteristic of homeopathic remedies; because the body systems are in equilibrium there is nothing to restore and the harmonisation or inductive properties of the homeopathic dose have no effect. The dose effect is experienced only where there is some physiological or symptomatological disruption of normal functionality.
Claims (5)
1. Use of a homeopathic dilution of a nicotine-containing extract of the plant Nicotiana tabacum in the manufacture of a medicament for use in a method of restoring neuronal function in a 5 subject whose neuronal function has been impaired.
2. Use according to Claim 1, wherein the medicament is used to induce normal neuronal function in a subject whose normal neuronal function has been impaired by exposure to and tolerance of nicotine.
3. Use according to Claim 2, wherein the medicament is used 10 as a palliative to relieve the withdrawal symptoms experienced by habitual users of tobacco products when the consumption of such products is interrupted.
4. Use according to Claim 1, wherein the medicament is used to correct a condition characterised by cerebral insufficiency. 15
5. A homeopathic dilution of a nicotine-containing extract of the plant Nicotiana tabacum wherein the final dilution contains a nicotine-potentiating agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IES960512 IES71050B2 (en) | 1996-07-15 | 1996-07-15 | Nicotine-containing homeopathic dilution and its use in restoring neuronal function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IES960512 IES71050B2 (en) | 1996-07-15 | 1996-07-15 | Nicotine-containing homeopathic dilution and its use in restoring neuronal function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IES71050B2 true IES71050B2 (en) | 1997-01-15 |
Family
ID=11041216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IES960512 IES71050B2 (en) | 1996-07-15 | 1996-07-15 | Nicotine-containing homeopathic dilution and its use in restoring neuronal function |
Country Status (1)
| Country | Link |
|---|---|
| IE (1) | IES71050B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120136020A1 (en) * | 2002-02-28 | 2012-05-31 | Sempach Pty Ltd | Treatment of effect of chemicals with their ultradilute stereoisomers |
-
1996
- 1996-07-15 IE IES960512 patent/IES71050B2/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120136020A1 (en) * | 2002-02-28 | 2012-05-31 | Sempach Pty Ltd | Treatment of effect of chemicals with their ultradilute stereoisomers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rose | Nicotine and nonnicotine factors in cigarette addiction | |
| Siegel | Herbal intoxication: Psychoactive effects from herbal cigarettes, tea, and capsules | |
| Covey et al. | Advances in non-nicotine pharmacotherapy for smoking cessation | |
| WO2003090798A1 (en) | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine | |
| RA et al. | Coca-paste smoking in some Latin American countries: a severe and unabated form of addiction | |
| WO2003090711A1 (en) | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine | |
| JP3051953B2 (en) | Anti-abstinence drug for poisoning patients, consisting of Bushi (sushi) -sulfur complex Chinese herbal preparation, and its manufacturing method | |
| Rose | Disrupting nicotine reinforcement: from cigarette to brain | |
| US20100113453A1 (en) | Sublingual Formulations of D-Cycloserine and Methods of Using Same | |
| Frishman | Smoking cessation pharmacotherapy | |
| US20050100513A1 (en) | Homeopathic method and system for treating nicotine addiction | |
| Müller et al. | The use of transdermal nicotine in smoking cessation | |
| Zaniewska et al. | Nicotine dependence—human and animal studies, current pharmacotherapies and future perspectives | |
| IE960511A1 (en) | Nicotine-containing homeopathic dilution and its use in¹restoring neuronal function | |
| IES71050B2 (en) | Nicotine-containing homeopathic dilution and its use in restoring neuronal function | |
| Brown et al. | “Legal Highs”–Constituents, Activity, Toxicology, and Herbal Folklore | |
| CN112043789B (en) | Composition for preventing or treating nicotine addiction comprising extract of radix Ophiopogonis of broad leaf as active ingredient | |
| US10098918B2 (en) | Vaporized medicants and methods of use | |
| KR920003913B1 (en) | Antidotes of noncotics addication and its preparation | |
| WO1995011678A1 (en) | Use of nicotine substitutes for the treatment of nicotine withdrawal | |
| US10918684B2 (en) | Vaporized medicants and methods of use | |
| US6552035B2 (en) | Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae | |
| JP7361076B2 (en) | testosterone booster | |
| KR100370390B1 (en) | Composition for inducing prohibition of smoking comprising alkaloids from Radix ipecauanhae | |
| Webb et al. | Nicotiana glauca toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |